| Titolo |
Pubblicato in |
Anno |
| Correctly marking the 70th anniversary of Castleman disease-Response |
BRITISH JOURNAL OF HAEMATOLOGY |
2024 |
| Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2024 |
| A Rare Case of Primary Bone Follicular Lymphoma with Multiple Osteolytic Lesions: A Case Report and Review of the Literature |
HEMATO |
2024 |
| Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results |
JOURNAL OF CLINICAL ONCOLOGY |
2024 |
| Efficacy of Residual Site Radiation Therapy (ISRT) in Patients
with Primary Mediastinal Lymphoma with Deauville Score 4
Following R-CHT: Results of a Retrospective Mono
Institutional Study |
JOURNAL OF CLINICAL MEDICINE |
2023 |
| Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin's disease |
FRONTIERS IN ONCOLOGY |
2023 |
| Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas |
HEMATOLOGICAL ONCOLOGY |
2023 |
| The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features |
BRITISH JOURNAL OF HAEMATOLOGY |
2023 |
| Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162 |
JOURNAL OF CLINICAL MEDICINE |
2023 |
| Angioimmunoblastic T-Cell Lymphoma with Exuberant CD30-Positive Follicular Dendritic Cell Proliferation in a SARS-CoV-2 Patient: The Role of Mutational Analysis to Exclude an Associated Follicular Dendritic Cell Sarcoma |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2022 |
| Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma |
JOURNAL OF CLINICAL MEDICINE |
2022 |
| IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study |
LEUKEMIA |
2022 |
| [18F]FDG PET/CT in Patients Affected by SARS-CoV-2 and Lymphoproliferative Disorders and Treated with Tocilizumab |
JOURNAL OF PERSONALIZED MEDICINE |
2022 |
| Arrhythmias and cardiogenic shock: a rare disease presentation of diffuse large B-cell lymphoma with cardiac involvement |
HEMATO |
2021 |
| Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study |
IN VIVO |
2020 |
| All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma |
CANCER CHEMOTHERAPY AND PHARMACOLOGY |
2020 |
| Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation |
BONE MARROW TRANSPLANTATION |
2019 |
| The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma |
INVESTIGATIONAL NEW DRUGS |
2019 |
| The neutrophil/lymphocyte ratio ≥3.5 is a prognostic marker in diffuse large B-cell lymphoma. a retrospective analysis from the database of the Italian regional network ‘Rete Ematologica del Lazio per i Linfomi’ (RELLI) |
LEUKEMIA & LYMPHOMA |
2019 |
| Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients |
ONCOIMMUNOLOGY |
2015 |
